Showing results (321-330 of 542) with videos related to
Sort By:
Pageof 55
Neurodegenerative Disease Management|January 25, 2020
Development of the MiNDToolkit for management of cognitive and behavioral impairment in motor neuron diseaseRatko Radakovic, Helen Copsey, Carmel Moore, et al.Neurodegenerative Disease Management|January 12, 2021
Omaveloxolone: potential new agent for Friedreich ataxiaDavid R Lynch, Joseph JohnsonNeurodegenerative Disease Management|September 30, 2022
Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practiceDimos Mitsikostas, Christos Bakirtzis, Ioannis Nikolaidis, et al.Neurodegenerative Disease Management|March 22, 2021
Opicapone for Parkinson's disease: clinical evidence and future perspectivesClémence Leung, Olivier Rascol, Margherita FabbriNeurodegenerative Disease Management|November 8, 2021
Tongue measurements and pharyngeal residue in amyotrophic lateral sclerosisMilena Magalhães Augusto, Roberta Gonçalves da Silva, Mario Emílio Teixeira Dourado Júnior, et al.Neurodegenerative Disease Management|February 1, 2021
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosisAugusto A Miravalle, Joshua Katz, Derrick Robertson, et al.Neurodegenerative Disease Management|January 12, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summaryJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.Neurodegenerative Disease Management|December 2, 2021
COVID-19-associated encephalitis or Creutzfeldt-Jakob disease: a case reportGooya Tayyebi, Seyed Kazem Malakouti, Behnam Shariati, et al.Neurodegenerative Disease Management|December 21, 2021
Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in GermanyTjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, et al.Neurodegenerative Disease Management|October 26, 2022
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapiesJohn Foley, Regina Berkovich, Mark Gudesblatt, et al.Pageof 55